Cryptotanshinone (Synonyms: 隐丹参酮; Cryptotanshinon; Tanshinone c)

目录号: HY-N0174 纯度: 98.70%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Cryptotanshinone是从丹参的根中提取的天然化合物，具有抗肿瘤活性。 Cryptotanshinone抑制 STAT3 的 IC₅₀ 为4.6 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cryptotanshinone Chemical Structure

CAS No. : 35825-57-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥355	In-stock
1 mg	￥109	In-stock
5 mg	￥218	In-stock
10 mg	￥350	In-stock
25 mg	￥621	In-stock
50 mg	￥950	In-stock
100 mg	￥1488	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Cryptotanshinone:

Cryptotanshinone (Standard) 询价

MCE 顾客使用本产品发表的 37 篇科研文献

: Cryptotanshinone purchased from MCE. Usage Cited in: Eur J Pharmacol. 2022 Nov 30;175434. [Abstract]; Cryptotanshinone (CTS; 0, 10, 20 μМ; 24 h) significantly decreases the expression of Col-I and (when at 20 μМ) Col-III, α-SMA, in WPMY-1 cells.

: Cryptotanshinone purchased from MCE. Usage Cited in: Eur J Pharmacol. 2022 Nov 30;175434. [Abstract]; Cryptotanshinone (CTS; 10, 20 μМ; 24 h) promotes apoptosis of BPH-1 (fig A) and WPMY-1 (fig B) cells.

Cryptotanshinone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

查看所有亚型

STAT3 STAT5 STAT6 STAT1

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC₅₀ of 4.6 μM.

IC₅₀ & Target^[1]

STAT3

4.6 μM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
AGS	IC₅₀	1.58 μM Compound: 3, cryptotanshinone	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
AGS	IC₅₀	10.2 μM Compound: 3, cryptotanshinone	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	13.5 μM Compound: 3, cryptotanshinone	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
BaF3	IC₅₀	17.22 μM Compound: Cryptotanshinone	Growth inhibition of IL3-stimulated mouse BA/F3 cells after 48 hrs by CellTiter 96 assay Growth inhibition of IL3-stimulated mouse BA/F3 cells after 48 hrs by CellTiter 96 assay	[PMID: 23957426]
ECa-109 cell line	IC₅₀	5.01 μM Compound: 8	Antitumor activity against human EC109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antitumor activity against human EC109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35504209]
HCT-116	IC₅₀	4.6 μM Compound: 47	Inhibition of STAT3 expressed in human HCT116 cells after 24 hrs by luciferase reporter gene assay Inhibition of STAT3 expressed in human HCT116 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22650325]
Hep 3B2	IC₅₀	> 30 μM Compound: 3, cryptotanshinone	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	> 30 μM Compound: 3, cryptotanshinone	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	1.36 μM Compound: 3, cryptotanshinone	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
HepG2	IC₅₀	29.2 μM Compound: 8	Antitumor activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35504209]
KB 3-1	IC₅₀	6.9 μM Compound: 1	Cytotoxicity against drug-sensitive human KB-3-1 cells after 48 hrs by MTS/PMS assay Cytotoxicity against drug-sensitive human KB-3-1 cells after 48 hrs by MTS/PMS assay	[PMID: 11720520]
KB-V1	IC₅₀	7.5 μM Compound: 1	Cytotoxicity against multidrug-resistant human KBV1 cells after 48 hrs by MTS/PMS assay Cytotoxicity against multidrug-resistant human KBV1 cells after 48 hrs by MTS/PMS assay	[PMID: 11720520]
MIA PaCa-2	IC₅₀	5.8 μM Compound: 14	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
Vero C1008	CC₅₀	> 300 μM Compound: 28	Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay	[PMID: 35620927]

体外研究
(In Vitro)

Cryptotanshinone 显著抑制 STAT3 依赖的荧光素酶活性、STAT3 Tyr705 磷酸化和 STAT3 二聚化，相比之下，Tanshinone IIA 不表现任何活性。Cryptotanshinone (7 μM) 显著阻断 DU145 细胞中 STAT3 Tyr705 磷酸化，但不影响 STAT3 Ser727 磷酸化，且以 IC₅₀ 约 5 μM 显著抑制 JAK2 的磷酸化，而不影响上游激酶 c-Src 和 EGFR 的磷酸化，表明 STAT3 Tyr705 磷酸化的抑制可能通过直接机制实现，可能是通过与 STAT3 的 SH2 结构域结合。Cryptotanshinone 显著抑制 DU145 前列腺癌细胞中具有活性 STAT3 的增殖，GI₅₀ 为 7 μM，作用机制是阻断 STAT3 活性，导致 cyclin D1、Bcl-xL 和 survivin 的下调，从而引起 G0-G1 期细胞累积。Cryptotanshinone 对 PC3、LNCaP 和 MDA-MB-468 细胞的增殖抑制作用较弱^[1]。Cryptotanshinone 显著减弱 DEX 对卵巢的激素效应，包括培养基中睾酮 (T) 的显著降低及孕酮 (P) 的升高。Cryptotanshinone 显著增加 DEX 处理的卵巢中 AKT2 和 GSK3β 的磷酸化水平^[2]。Cryptotanshinone 和 Imatinib 联合处理对 Imatinib 敏感和耐药的慢性粒细胞白血病 (CML) 细胞系以及原代 CML 细胞表现出显著的协同杀伤作用^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Cryptotanshinone 可逆转卵巢 IR，并显著增加接受 DEX 治疗的小鼠所有检查组织中的 2-脱氧-D-[1,2-³H]-葡萄糖摄取量。Cryptotanshinone 可显著降低排卵率和血浆 E2 和 P 水平^[2]。Cryptotanshinone 给药可显著降低 ob/ob 小鼠 (C57BL/6J-Lepob) 和饮食诱导肥胖 (DIO) 小鼠的体重和食物摄入量，且呈剂量依赖性。与对照组小鼠相比，Cryptotanshinone 可显著减少脂肪组织中的脂肪，显著降低血清甘油三酯和胆固醇水平，骨骼肌的 AMPK 活性提高 2.5 至 3 倍。以 600 mg/kg/天的剂量口服Cryptotanshinone 可显著降低 ob/ob 小鼠 (C57BL/6J-Lepob)、db/db 小鼠 (C57BL/KsJ-Leprdb) 和 ZDF 大鼠的血糖水平，这种效果在 3 天后出现，并持续整个监测期^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

296.36

Formula

C₁₉H₂₀O₃

CAS 号

35825-57-1

性状

固体

颜色

Pink to red

中文名称

隐丹参酮；隐丹参醌；丹参酮 C

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : 5 mg/mL (16.87 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3743 mL	16.8714 mL	33.7427 mL
5 mM	0.6749 mL	3.3743 mL	6.7485 mL
10 mM	0.3374 mL	1.6871 mL	3.3743 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.83 mg/mL (2.80 mM); 悬浊液; 超声助溶

此方案可获得 0.83 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (2.80 mM); 澄清溶液

此方案可获得 ≥ 0.83 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 0.83 mg/mL (2.80 mM); 澄清溶液

此方案可获得 ≥ 0.83 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Corn Oil
Solubility: 8 mg/mL (26.99 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.70%

选择批次：

Data Sheet (675 KB) SDS (623 KB)

COA (296 KB) HNMR (242 KB) RP-HPLC (246 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Shin DS, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009 Jan 1;69(1):193-202. [Content Brief]

[2]. Huang Y, et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 2014 Aug;102(2):589-596.e4. [Content Brief]

[3]. Ge Y, et al. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Leuk Lymphoma. 2014 Jun 25:1-9. [Content Brief]

[4]. Kim EJ, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol. 2007 Jul;72(1):62-72. Epub 2007 Apr 11. [Content Brief]

Kinase Assay ^[1]	HCT-116 cells are transiently transfected with reporter plasmid having the STAT3-binding element for regulating luciferase assay. Cells are treated with Cryptotanshinone for 24 hours at a concentration range of 0.2 to 50 μM. After treatment, cells are harvested in 20 μL of passive lysis buffer and luciferase activity is evaluated by the Dual Luciferase Reporter Assay kit on Wallac Victor2. The concentration of Cryptotanshinone that inhibits the luciferase activity by 50% represents IC₅₀ value. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[3]	The MTT assay is used for the assessment of cell growth inhibition as described previously. Cells are seeded at a density of 8000 cells per well in 96-well plates in RPMI-1640 containing 10% FBS. Different concentrations of imatinib and CPT are added and incubated for another 24 h. Then, 20 μL of MTT are added into each well and the absorbance at 570 nm is measured on an enzyme linked immunosorbent assay (ELISA) plate reader. The coefficient of drug interaction (CDI) between imatinib and CPT is determined according to a previous study. The calculated method is as follows: CDI/AB/(A × B). According to the absorbance of each group, AB is the ratio of the combination group to the control group; A or B is the ratio of the single agent group to the control group. CDI < 1 indicates a synergistic effect; CDI=1 indicates an additive effect; CDI > 1 indicates an antagonistic effect. In the combination treatment group, the concentrations of CPT are arbitrarily designated according to the 50% inhibitory concentration (IC₅₀) value. Then, the cell viabilities are determined after treatment with different concentrations of imatinib plus CPT (constant CPT concentration for one cell type). Finally, the combination IC₅₀ values of imatinib are calculated, and are represented in Table I. The primary CML cells CP1 to CP3 are isolated from patients in chronic phase, while BC1 and BC2 are isolated from patients in blast crisis. Three independent sets of experiments are performed. The IC₅₀ values are presented as the mean±standard deviation (SD). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Shin DS, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009 Jan 1;69(1):193-202. [Content Brief] [2]. Huang Y, et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 2014 Aug;102(2):589-596.e4. [Content Brief] [3]. Ge Y, et al. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Leuk Lymphoma. 2014 Jun 25:1-9. [Content Brief] [4]. Kim EJ, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol. 2007 Jul;72(1):62-72. Epub 2007 Apr 11. [Content Brief]

Cryptotanshinone 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3743 mL	16.8714 mL	33.7427 mL	84.3569 mL
	5 mM	0.6749 mL	3.3743 mL	6.7485 mL	16.8714 mL
	10 mM	0.3374 mL	1.6871 mL	3.3743 mL	8.4357 mL
	15 mM	0.2250 mL	1.1248 mL	2.2495 mL	5.6238 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cryptotanshinone35825-57-1Cryptotanshinon Tanshinone c隐丹参酮隐丹参醌丹参酮 CSTATAutophagyInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Cryptotanshinone (Synonyms: 隐丹参酮; Cryptotanshinon; Tanshinone c)

Customer Review

Other Forms of Cryptotanshinone:

MCE 顾客使用本产品发表的 37 篇科研文献

Cryptotanshinone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Cryptotanshinone 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Cryptotanshinone (Synonyms: 隐丹参酮; Cryptotanshinon; Tanshinone c)

Customer Review

Other Forms of Cryptotanshinone:

Cryptotanshinone 相关抗体

MCE 顾客使用本产品发表的 37 篇科研文献

Cryptotanshinone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Cryptotanshinone 相关抗体:

摩尔计算器

稀释计算器

Cryptotanshinone 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z